Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

By sjmartinez • December 11, 2024

Pollack CV Jr, Arroyo D, Kanda E, Lázaro IJS, Lesén E, Franzén S, Gray CM, Lipińska A, Murohara T, Rastogi A. Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode. ESC Heart Fail. 2024 Dec 10. doi: 10.1002/ehf2.15171. Epub ahead of print. PMID: 39659133.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Potassium binder, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

Transport mechanism of the SLC4 proteins – lessons from recent structural and computational studies

Zhekova HR, Pushkin A, Wang W, Kao L, Tsirulnikov K, Azimov R, Abuladze N, Acuna D, Zhou ZH, Tieleman DP, Kurtz I. Transport mechanism of[...]

Muscle Matters: Poor Muscle Quality Increases Mortality Risk in Early CKD

Hamdan H, Roshanravan B, Kalantar-Zadeh K. Muscle Matters: Poor Muscle Quality Increases Mortality Risk in Early CKD. Clin J Am Soc Nephrol. 2026 May 15.[...]

Hemodialysis Modality and Mortality Outcomes among Incident Dialysis Patients: An International Cohort Study Comparing High-Volume Hemodiafiltration and Hemodialysis

Zhang Y, Winter A, Ficociello LH, Arya S, Stuard S, Usvyat LA, Kalantar-Zadeh K. Hemodialysis Modality and Mortality Outcomes among Incident Dialysis Patients: An International[...]